Literature DB >> 8866701

Altered platelet peripheral-type benzodiazepine receptor in posttraumatic stress disorder.

M Gavish1, N Laor, M Bidder, D Fisher, O Fonia, U Muller, A Reiss, L Wolmer, L Karp, R Weizman.   

Abstract

Peripheral-type benzodiazephine receptors (PBR) are involved in steroidogenesis and are sensitive to stress. Reduced platelet PBR density has been demonstrated in generalized anxiety disorder (GAD), but not in obsessive-compulsive disorder (OCD). We extended this observation to another anxiety disorder, namely, posttraumatic stress disorder (PTSD). Eighteen post-Persian Gulf War PTSD patients and 17 age- and sex-matched controls were included in the study. All subjects were evaluated using the Structured Clinical Interview for DSM-III-R-Patient Version. The severity of symptoms was assessed using the DSM-III-R scale for PTSD, the Impact of Event Scale, the Beck Depression Inventory, and the State-Trait Anxiety Inventory. [3H]PK 11195 was used to label platelet PBR. All psychological parameters (except trait anxiety) were higher in PTSD patients compared to controls. Decreased platelet PBR density (-62%; p < .001) was observed in the PTSD patients compared to controls. The reduction in PBR observed in PTSD patients was in accordance with the findings in GAD patients, but differed from those obtained in OCD patients. It is possible that the receptoral downregulation is an adaptive response aimed at preventing chronic overproduction of glucocorticoids in hyperarousal states.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8866701     DOI: 10.1016/0893-133X(95)00078-R

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  8 in total

1.  Peripheral-type benzodiazepine receptor binding sites in platelets of patients with panic disorder associated to separation anxiety symptoms.

Authors:  Stefano Pini; Claudia Martini; Marianna Abelli; Matteo Muti; Camilla Gesi; Marina Montali; Beatrice Chelli; Antonio Lucacchini; Giovanni B Cassano
Journal:  Psychopharmacology (Berl)       Date:  2005-10-14       Impact factor: 4.530

Review 2.  Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders.

Authors:  Rainer Rupprecht; Vassilios Papadopoulos; Gerhard Rammes; Thomas C Baghai; Jinjiang Fan; Nagaraju Akula; Ghislaine Groyer; David Adams; Michael Schumacher
Journal:  Nat Rev Drug Discov       Date:  2010-12       Impact factor: 84.694

Review 3.  Translocator protein (18kDa) TSPO: a new diagnostic or therapeutic target for stress-related disorders?

Authors:  Rainer Rupprecht; Christian H Wetzel; Mario Dorostkar; Jochen Herms; Nathalie L Albert; Jens Schwarzbach; Michael Schumacher; Inga D Neumann
Journal:  Mol Psychiatry       Date:  2022-04-20       Impact factor: 15.992

Review 4.  Post-traumatic stress disorder: the neurobiological impact of psychological trauma.

Authors:  Jonathan E Sherin; Charles B Nemeroff
Journal:  Dialogues Clin Neurosci       Date:  2011       Impact factor: 5.986

5.  Neurosteroids as neuromodulators in the treatment of anxiety disorders.

Authors:  Patrizia Longone; Flavia di Michele; Elisa D'Agati; Elena Romeo; Augusto Pasini; Rainer Rupprecht
Journal:  Front Endocrinol (Lausanne)       Date:  2011-10-19       Impact factor: 5.555

Review 6.  Tetrapyrroles as Endogenous TSPO Ligands in Eukaryotes and Prokaryotes: Comparisons with Synthetic Ligands.

Authors:  Leo Veenman; Alex Vainshtein; Nasra Yasin; Maya Azrad; Moshe Gavish
Journal:  Int J Mol Sci       Date:  2016-06-04       Impact factor: 5.923

7.  Estradiol modulates translocator protein (TSPO) and steroid acute regulatory protein (StAR) via protein kinase A (PKA) signaling in hypothalamic astrocytes.

Authors:  Claire Chen; John Kuo; Angela Wong; Paul Micevych
Journal:  Endocrinology       Date:  2014-05-30       Impact factor: 4.736

8.  Expression and purification of the mammalian translocator protein for structural studies.

Authors:  Elisabeth Graeber; Volodymyr M Korkhov
Journal:  PLoS One       Date:  2018-06-13       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.